ルビコン研究所のIPOはデビューで27.8%の急上昇,強い需要と堅実な財政力で急上昇した. Rubicon Research's IPO surged 27.8% on debut, fueled by strong demand and solid financials.

ルビコンリサーチは2025年10月16日にインドの株式取引所で強なデビューを遂げ,株式はIPO価格の485ドル以上で27.8%開店し,BSEとNSEの両方で620ドルで取引されました. Rubicon Research made a strong debut on India’s stock exchanges on October 16, 2025, with shares opening 27.8% above the IPO price of ₹485, trading at ₹620 on both the BSE and NSE. 投資額1,377.5億円のIPOは,合格した機関購入者および非機関投資家の強い関心により,総計103.9倍の購読率で圧倒的な需要を記録しました. The ₹1,377.5 crore IPO saw overwhelming demand, subscribing 103.9 times overall, driven by strong interest from qualified institutional buyers and non-institutional investors. 米国市場に焦点をあてたプロの製薬メーカーは,FY25で強い財政成果を報告し,49%の収入の増加と高い利益を生んだ. The company, a specialty pharmaceutical manufacturer focused on the U.S. market, reported strong financial performance in FY25, with 49% revenue growth and high profitability. 新たに掲げる事業は,債務削減,取得,成長の推進に用いられる. Proceeds from the fresh issue will be used for debt reduction, acquisitions, and growth initiatives.